Personalized intensification of treatment for hormone-sensitive prostate cancer nature.com/articles/s41571-0… Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology. Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care. @drcilento @LisaButler5 @drlouiseemmett @ChrisSweens1 @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists